SQZ Biotechnologies (NYSE: SQZ) is one of 197 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare SQZ Biotechnologies to similar companies based on the strength of its profitability, dividends, earnings, analyst recommendations, valuation, institutional ownership and risk.
Earnings & Valuation
This table compares SQZ Biotechnologies and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|SQZ Biotechnologies||$21.00 million||-$50.52 million||-1.44|
|SQZ Biotechnologies Competitors||$606.09 million||$28.84 million||24.48|
This is a breakdown of current ratings and target prices for SQZ Biotechnologies and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|SQZ Biotechnologies Competitors||1115||4439||9773||185||2.58|
SQZ Biotechnologies currently has a consensus target price of $38.33, suggesting a potential upside of 183.95%. As a group, “Biological products, except diagnostic” companies have a potential upside of 28.69%. Given SQZ Biotechnologies’ stronger consensus rating and higher probable upside, equities research analysts clearly believe SQZ Biotechnologies is more favorable than its competitors.
Institutional and Insider Ownership
39.3% of SQZ Biotechnologies shares are owned by institutional investors. Comparatively, 52.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.8% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares SQZ Biotechnologies and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|SQZ Biotechnologies Competitors||-22,838.38%||-121.87%||-32.56%|
About SQZ Biotechnologies
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.